

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE <b>35 Years</b>	3. SEX <b>Male</b>	3a. WEIGHT <b>Unk</b>	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY  <input type="checkbox"/> OTHER
		Day	Month	Year				Day	Month	Year	
			<b>PRIVACY</b>					<b>Unk</b>			

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)  
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)  
**Nausea [Nausea]**  
**Paresthesia [Paresthesia]**

Case Description: This spontaneous case was received from a Physician in COSTA-RICA.

The patient was a 35-year-old male with an unknown medical history was treated with NATRILIX SR 1.5MG (unknown daily dose) since an unknown date for an unknown indication.

(Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) <b>#1 ) NATRILIX SR (INDAPAMIDE 1.5 mg) Coated tablet, 1.5 mg</b>		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) <b>#1 ) UNK</b>	16. ROUTE(S) OF ADMINISTRATION <b>#1 ) Unknown</b>	
17. INDICATION(S) FOR USE <b>#1 ) (Product used for unknown indication)</b>		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) <b>#1 ) Unknown</b>	19. THERAPY DURATION <b>#1 ) Unknown</b>	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
Unknown		

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER <b>Servier PANAMA COSTA RICA</b>		26. REMARKS
	24b. MFR CONTROL NO. <b>S25006024</b>	
24c. DATE RECEIVED BY MANUFACTURER <b>28-APR-2025</b>	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT <b>05-MAY-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	
25b. NAME AND ADDRESS OF REPORTER <b>NAME AND ADDRESS WITHHELD.</b>		

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

No other concomitant medication was reported, if any

On an unknown date, the patient experienced nausea and paresthesia.

On an unknown date, 3 days after discontinuation of NATRILIX SR 1.5MG, patient recovered.

Action taken regarding NATRILIX SR 1.5MG: Drug withdrawn.

Outcome: Recovered.

Reporter's causality assessment and event seriousness were not reported.

Case Comment: Nausea and Paraesthesia are listed as per RSI of NATRILIX SR (INDAPAMIDE). Considering the known side effect with missing information (medical history, definitive therapy and event dates, indication, investigations) the causal role is possible.